Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.

[1]  William L Jorgensen,et al.  Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design. , 2012, Journal of the American Chemical Society.

[2]  Bingjie Qin,et al.  Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. , 2012, Journal of medicinal chemistry.

[3]  Li Huang,et al.  Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[4]  Robert A. Domaoal,et al.  Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase. , 2012, Bioorganic & medicinal chemistry letters.

[5]  William L Jorgensen,et al.  Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. , 2011, Journal of medicinal chemistry.

[6]  William L. Jorgensen,et al.  Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. , 2011, Journal of the American Chemical Society.

[7]  A. Lazzarin,et al.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial , 2011, The Lancet.

[8]  William L. Jorgensen,et al.  Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. , 2010, Bioorganic & medicinal chemistry letters.

[9]  Christopher D Miller,et al.  Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents , 2010, The Annals of pharmacotherapy.

[10]  A. L. L. East,et al.  pKa Values of Some Piperazines at (298, 303, 313, and 323) K , 2009 .

[11]  William L Jorgensen,et al.  Efficient drug lead discovery and optimization. , 2009, Accounts of chemical research.

[12]  Mukul Singh,et al.  Sustained release of microbicides by newly engineered vaginal rings , 2009, AIDS.

[13]  D. Hazuda,et al.  The Challenge of Finding a Cure for HIV Infection , 2009, Science.

[14]  P. Naidoo,et al.  Exploring the use of novel drug delivery systems for antiretroviral drugs. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  Joseph D. Bauman,et al.  Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design , 2008, Nucleic acids research.

[16]  Stephen H Hughes,et al.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations , 2008, Proceedings of the National Academy of Sciences.

[17]  J. Comer,et al.  Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. , 2008, Journal of Pharmaceutical and Biomedical Analysis.

[18]  William L Jorgensen,et al.  Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[19]  Julian Tirado-Rives,et al.  Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[20]  Stephen H Hughes,et al.  In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). , 2005, Journal of medicinal chemistry.

[21]  Paul J Lewi,et al.  Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. , 2005, Journal of medicinal chemistry.

[22]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[23]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[24]  Marie-Pierre de Béthune,et al.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.

[25]  Dale E. Johnson,et al.  Current HIV therapeutics: mechanistic and chemical determinants of toxicity. , 2009, Current opinion in drug discovery & development.